Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-01D-351 (Livzon Pharmaceutical Group Inc.)
- Development stage
- Unknown
- Lead developer
- Livzon Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V-01D-351 is a bivalent recombinant protein subunit vaccine developed by Livzon Pharmaceutical Group for the prevention of COVID-19. It is composed of two recombinant fusion proteins: one derived from the SARS-CoV-2 Beta variant (V-01-351) and the other from the Delta variant (V-01D). The vaccine platform utilizes a fusion protein design where the receptor-binding domain (RBD) of the spike protein is fused to an immunopotentiator to enhance immunogenicity. It is primarily investigated as a heterologous booster dose in adults who have previously received inactivated COVID-19 vaccines to broaden protection against emerging variants.
- Other names
- recombinant SARS-CoV-2 beta variant fusion protein vaccine + recombinant SARS-CoV-2 delta variant fusion protein vaccineV-01-351/V-01D Bivalence VaccineLivzon bivalent COVID-19 vaccine
02
Targets
BCR-SARS-CoV-2-S-RBD (B-cell receptor specific for SARS-CoV-2 spike protein receptor-binding domain)FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on V-01D-351 (Livzon Pharmaceutical Group Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-01D-351 (Livzon Pharmaceutical Group Inc.).